Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase III CANOVA study results show PFS 9.9 months with venetoclax/dex vs 5.8 months with pomalidomide/dex (P=0.24); ORR and VGPR 62% and 39% vs. 35% and 14%; MRD negativity 8% vs. 0%; median OS 32.4 months vs 26.9 months; Grade ≥3 TEAEs 67% vs. 83%.”
Title: Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Authors: Rakesh Popat, Meral Beksac, Meletios A. Dimopoulos, Moshe E. Gatt, Francesca Gay, Jae-Cheol Jo, Prashant Kapoor, Eirini Katodritou, K. Martin Kortüm, Silvia Ling, Chandramouli Nagarajan, Kenshi Suzuki, Lugui Qiu, Maika Onishi, Grace Ku, Monique Dail, Nabanita Mukherjee, Jeremy A. Ross, Mohamed Ali Badawi, Mary Jean Fusco, Edyta Dobkowska, Emma Arriola, Orlando F. Bueno, Nizar J. Bahlis, Shinsuke Iida, Philippe Moreau, Jason Valent, and María-Victoria Mateos.
You can read the Full Article in the Journal of Clinical Oncology.
You can find more posts featuring Robert Orlowski on OncoDaily.
